*ST Leisure announced that the holding subsidiary Kangle Guard Biotechnology Co., Ltd. recently received the “Drug Registration Certificate” for the trivalent human papillomavirus vaccine approved by the State Drug Administration and approved the marketing of this prophylactic biological product. The vaccine is suitable for women aged 9-45 to prevent diseases such as cervical cancer caused by HPV 16, 18, and 58 virus infections. It is the company's first vaccine product approved for marketing.

*ST Leisure announced that the holding subsidiary Kangle Guard Biotechnology Co., Ltd. recently received the “Drug Registration Certificate” for the trivalent human papillomavirus vaccine approved by the State Drug Administration and approved the marketing of this prophylactic biological product. The vaccine is suitable for women aged 9-45 to prevent diseases such as cervical cancer caused by HPV 16, 18, and 58 virus infections. It is the company's first vaccine product approved for marketing.